Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from TrivarX Limited ( (AU:TRI) ).
TrivarX has appointed radiopharmaceutical and biotech veteran Dr Danielle Meyrick as chief executive officer from 1 June 2026 to lead clinical and commercial development of its Stabl-Im brain cancer imaging platform. With more than two decades in oncology, nuclear medicine and isotope-based technologies at Telix Pharmaceuticals, ITM Isotopes and GenesisCare, she is expected to accelerate trial execution, regulatory engagement and commercial strategy for the technology, which aims to offer a safe, non-invasive alternative for imaging and monitoring brain tumours.
The company is progressing preparations for its first in-human clinical studies of Stabl-Im, with advanced negotiations underway with leading contract research organisations to support trial design, site activation and program delivery. TrivarX says it remains well funded and on schedule to complete a Phase 1 study this year, positioning the Stabl-Im platform closer to clinical validation and potentially strengthening the company’s standing in the neuro-oncology imaging market if outcomes are positive.
More about TrivarX Limited
TrivarX Limited is an ASX-listed healthcare technology company developing innovative diagnostic and imaging solutions focused on mental health and neuro-oncology. Its key asset, the Stabl-Im platform, uses stable isotope labelling with standard MRI to safely image and monitor brain cancers by visualising replicating cells and cellular activity in real time.
YTD Price Performance: -15.79%
Average Trading Volume: 1,469,953
Technical Sentiment Signal: Sell
Current Market Cap: A$18.46M
For detailed information about TRI stock, go to TipRanks’ Stock Analysis page.